Cash PositionThe company has ~$100M in cash to explore new opportunities, focusing on potentially in-licensing assets preferably in the oncology space and evaluating potential reverse merger opportunities.
Oncology ExpertiseThe team's established record in oncology drug development may facilitate discussions around outside development candidates in that category.
Strategic OptionsEPIX is engaging in a strategic review to identify external opportunities to maximize shareholder value, including but not limited to in-licensing external assets and reverse mergers.